Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

MINIMAL SAPONIN-BASED ADJUVANT VACCINE PLATFORM

Project description

Optimised adjuvants for potent vaccines

Vaccines utilise adjuvants to enhance and boost the immune response to the vaccine’s antigens. Adjuvants can stimulate the immune system and enhance antigen presentation, thereby promoting a stronger and more prolonged immune response. The ERC-funded ADJU-PLATFORM project aims to produce a potent yet safe saponin adjuvant using a previously developed synthetic platform. Compared to traditional adjuvants, ADJU-PLATFORM solutions offer high purity, modular design and cost efficiency, leading to improved vaccines. Researchers plan to optimise intellectual property strategies and build a commercialisation roadmap for accelerated market entry of vaccine solutions across multiple disease areas.

Objective

ADJU-PLATFORM seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the efficient production of optimised saponin adjuvants and improved cost-effective vaccines. We have recently developed in the laboratory a potent, safe, stable and streamlined platform based on an optimised version of the vaccine adjuvant QS-21 that has led to patent applications and raised the interest of the pharmaceutical industry. In this PoC project, we aim to exploit our synthetic saponin technology to produce scalable adjuvant and vaccine candidates that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate our innovative minimal adjuvant platform in relevant settings for the advancement of novel adjuvant prototypes and molecular vaccines closer to the market.

The breakthrough innovation potential of ADJU-PLATFORM lies in the exploitation of this adjuvant vaccine platform for its application with additional formulation systems in a range of disease areas, expanding and improving the available vaccine solutions. The high purity and excellent chemical control over our synthetic platform compared to the heterogeneous natural product adjuvants, as well as its streamlined, modular nature and low-cost profile are distinctive attributes of our technology that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are (1) demonstrate our synthetic technology platform for the streamlined and efficient development of scalable adjuvant and vaccine solutions and (2) implement valorisation opportunities of our platform and products by establishing an optimal IPR strategy and a go-to-market roadmap for the commercialisation.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2022-POC1

See all projects funded under this call

Host institution

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
PARQUE TECNOLOGICO EDIFICIO 801 A
48160 DERIO VIZCAYA
Spain

See on map

Region
Noreste País Vasco Gipuzkoa
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0